Keep Me Logged In
Biotech company 23andMe offered low-cost personalized DNA analysis to help customers make informed health care decisions. CNBC's Julia Boorstin reports the company is back after the FDA put the tests on pause in 2013.
Got a confidential news tip? We want to hear from you.
Sign up for free newsletters and get more CNBC delivered to your inbox
© 2019 CNBC LLC. All Rights Reserved. A Division of NBCUniversal
Data is a real-time snapshot *Data is delayed at least 15 minutes. Global Business and Financial News, Stock Quotes, and Market Data and Analysis.
Data also provided by